Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

J&J-AbbVie cancer drug Imbruvica succeeds in late-stage trial

Johnson and Johnson said a combination therapy containing the company’s blockbuster cancer drug Imbruvica significantly improved survival in blood cancer patients, compared with drugs currently used as the standard of care.

Read More »

Johnson & Johnson’s multiple myeloma drug reduces risk of death in late-stage study

Johnson & Johnson’s blockbuster blood cancer drug Darzalex significantly reduced the risk of disease progression or death in patients who have not been previously treated for multiple myeloma, late-stage study data showed.

Read More »

High-cost Gilead cell therapy proves durable for some lymphoma patients

Nearly 40 percent of lymphoma patients treated with a single infusion of Gilead Sciences Inc.’s Yescarta were still responding to the cell therapy after at least two years of follow-up.

Read More »

Top Predictions for 2019 by Biopharma Execs

Biopharma executives were asked to predict what the next year might reveal.

Read More »

FDA approves Empliciti for new MM indication

Bristol-Myers Squibb snagged regulatory approval from the U.S. FDA for Empliciti (elotuzumab) for adults with multiple myeloma who have received at least two prior therapies.

Read More »

Novartis plans for 60 regulatory filings during 2019-2021

Swiss pharma giant Novartis announced plans to seek regulatory approval for 60 new treatments between 2019 and 2021.

Read More »

AbbVie, Roche combo treatment meets main goal of leukemia trial

AbbVie and Roche’s targeted therapy delayed the progression of a type of blood and bone marrow cancer when used in combination with the Swiss drugmaker’s cancer drug in a late-stage trial.

Read More »

AstraZeneca digs deeper into cancer with Innate stake

AstraZeneca is plowing deeper into cancer immunotherapy through a wide-ranging deal with Innate Pharma, which includes the British group buying a 9.8 percent stake in the French biotech company.

Read More »

U.S. FDA panel backs Celltrion biosimilar

An advisory panel to the U.S. Food and Drug Administration voted unanimously in favor of Celltrion Pharm Inc.’s copycat drug of Roche Holding AG’s blood cancer drug Rituxan.

Read More »

Seattle Genetics’ Adcetris Has Potential to Change Treatment for T-Cell Lymphoma

Seattle Genetics and development partner Takeda Pharmaceutical announced stellar Phase III data from the ECHELON-2 clinical trial of Adcetris (brentuximab vedotin) for peripheral T-cell lymphoma.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2018 Focus: Top 50 Pharma, Company of the Year and more!


Ad Right Bottom